SynthesisFrontiers in pharmacology2024
Efficacy and safety of traditional Chinese medicine decoction as an adjuvant treatment for diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects and safety of Salvia miltiorrhiza on the improvement of renal function, inflammatory factors, and vascular endothelium in patients with diabetic kidney disease: a meta-analysis and systematic review.Frontiers in pharmacology · 2025Pooled it
- Modified Shen-Yan-Fang-Shuai formula attenuates diabetic kidney disease progression via regulation of HIF-1α-mediated mitochondrial energy metabolism.Chinese medicine · 2026Article
- Global Research Trends in Traditional Chinese Medicine for Diabetic Kidney Disease: A 20-Year Bibliometric Analysis.Journal of inflammation research · 2026Review
- Unraveling the Mechanism of Tangmaikang Granules in Treating Diabetic Kidney Disease Based On UPLC-MS/MS, Network Pharmacology, Molecular Docking, Molecular Dynamics Simulations, and Experimental Validation.Current pharmaceutical biotechnology · 2026Article
- Gut Microbiota Dysbiosis and Metabolite Imbalance Mediate Diabetic Kidney Disease Inflammation: Mechanisms and Intervention Strategies Targeting Gut-Kidney Axis and NF-κB/NLRP3 Pathways.Journal of inflammation research · 2026Review
- Natural products in treating diabetic kidney disease: a visualized bibliometric analysis.Frontiers in pharmacology · 2025Article
- Molecular mechanisms and multi-target therapeutic strategies of diabetic nephropathy: from pathogenesis to precision interventions.Frontiers in pharmacology · 2025Review
- Combined bailing capsule and conventional therapies in the treatment of chronic renal failure: a meta-analysis and economic evaluation.Frontiers in medicine · 2025Article
- Research on TCM Comprehensive Treatment of DKD Based on Pathophysiological Mechanism.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Fecal microbiota transplantation is a promising therapy for kidney diseases.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.